Ascendis Pharma A/S (NASDAQ:ASND) Downgraded by BidaskClub to Strong Sell

BidaskClub cut shares of Ascendis Pharma A/S (NASDAQ:ASND) from a sell rating to a strong sell rating in a research report report published on Thursday morning, BidAskClub reports.

Several other brokerages have also commented on ASND. Zacks Investment Research upgraded Ascendis Pharma A/S from a sell rating to a hold rating in a research note on Tuesday, August 27th. Canaccord Genuity upped their price target on Ascendis Pharma A/S from $133.00 to $144.00 and gave the stock a buy rating in a research note on Friday, May 31st. Wedbush restated a buy rating and set a $223.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, June 28th. Finally, JPMorgan Chase & Co. upped their price target on Ascendis Pharma A/S from $143.00 to $152.00 and gave the stock an overweight rating in a research note on Thursday, August 29th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $153.29.

NASDAQ:ASND traded down $0.85 on Thursday, hitting $103.72. 133,245 shares of the stock were exchanged, compared to its average volume of 202,170. The stock has a market cap of $4.44 billion, a PE ratio of -27.73 and a beta of 0.64. The company has a current ratio of 11.59, a quick ratio of 11.59 and a debt-to-equity ratio of 0.05. The stock has a fifty day moving average of $113.12 and a 200-day moving average of $115.49. Ascendis Pharma A/S has a fifty-two week low of $53.21 and a fifty-two week high of $133.96.



Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Wednesday, August 28th. The biotechnology company reported ($1.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by ($0.08). The firm had revenue of $3.61 million for the quarter, compared to analyst estimates of $0.68 million. Ascendis Pharma A/S had a negative return on equity of 35.99% and a negative net margin of 932.52%. As a group, analysts predict that Ascendis Pharma A/S will post -5.31 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Atria Investments LLC boosted its position in shares of Ascendis Pharma A/S by 10.3% in the second quarter. Atria Investments LLC now owns 4,466 shares of the biotechnology company’s stock worth $509,000 after buying an additional 417 shares during the period. Mackenzie Financial Corp purchased a new stake in shares of Ascendis Pharma A/S in the second quarter worth about $872,000. Chartwell Investment Partners LLC boosted its position in shares of Ascendis Pharma A/S by 1.4% in the second quarter. Chartwell Investment Partners LLC now owns 20,917 shares of the biotechnology company’s stock worth $2,409,000 after buying an additional 280 shares during the period. International Biotechnology Trust PLC boosted its position in shares of Ascendis Pharma A/S by 87.0% in the second quarter. International Biotechnology Trust PLC now owns 25,800 shares of the biotechnology company’s stock worth $2,969,000 after buying an additional 12,000 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Ascendis Pharma A/S by 53.7% in the second quarter. Price T Rowe Associates Inc. MD now owns 7,178,036 shares of the biotechnology company’s stock worth $826,551,000 after buying an additional 2,509,034 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Featured Story: Support Level

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.